Stroke in Myopathies

Josef Finsterer\textsuperscript{a} Claudia Stöllberger\textsuperscript{b}

\textsuperscript{a}Neurological Department and \textsuperscript{b}Second Medical Department, Krankenanstalt Rudolfstiftung, Vienna, Austria

Key Words
Genetics · Myocardium · Dilated cardiomyopathy · Atrial fibrillation · Neuromuscular disorder · Cerebral infarction · Stroke-like episode

Abstract

Objectives: Only few data are available about the risk of myopathy patients experiencing a cerebral stroke. Aims: To review the current knowledge about the frequency, pathogenesis, and outcome of stroke in primary/secondary myopathies. Methods: Literature review of all human studies dealing with stroke in primary/secondary myopathies. Results: Stroke in myopathies may be either ischemic, metabolic, or cryptogenic. Ischemic stroke may be further classified as cardioembolic, angiopathic, hemodynamic, or thrombophilic. Cardioembolic stroke occurs if there is cardiac involvement in the form of atrial fibrillation/flutter, dilated cardiomyopathy, or non-compaction. Angiopathic stroke occurs if there is atherosclerosis (frequently associated with mitochondrial disorders (MIDs), vasculitis, or dissection in inflammatory myopathies) or MIDs. Thrombophilic stroke may occur in poly-/dermatomyositis if there is additional antiphospholipid syndrome. Metabolic stroke usually manifests as stroke-like episode and is a distinct feature of various MIDs, particularly MELAS syndrome. Metabolic stroke usually manifests as stroke-like episode and is a distinct feature of various MIDs, particularly MELAS syndrome. Differentiation between ischemic and metabolic stroke is essential in terms of diagnosis, therapy, and prognosis. Conclusions: Ischemic stroke due to cardioembolism, arteriopathy, or thrombophilia are rare events in myopathies, but metabolic stroke is a frequent feature of MIDs, with distinct diagnostic and therapeutic implications.
of stroke in MPs – from among 52 patients with Duchenne muscular dystrophy (DMD), 61 patients with myotonic dystrophy (dystrophia myotonica) type 1 (DM1), 14 patients with Becker’s muscular dystrophy (BMD), and 4 patients with Friedreich’s ataxia, collected during a period of 18 years and followed up every 6 months for 3–17 years – the prevalence of stroke was only 1.5%, and thus not increased compared to the non-myopathic population [1]. Among the 2 patients who experienced a stroke, 1 had DM1 and the other Friedreich’s ataxia. Both patients had atrial fibrillation (AFI)/atrial flutter (AFL) and both patients presented with reduced systolic function [1], the reason why stroke was attributed to cardioembolism in both patients. The low rate of stroke in this study may be due to the restriction of the study to only 3 types of primary MPs. Since a total of 4 patients of the cohort had AFI/AFL, 50% of these patients developed a stroke [1]. The frequency of stroke in DMD has been systematically investigated by Hanajima and Kawai [2] in Japan. Among 665 DMD patients, stroke occurred in 5 of them (0.75%) [2]. All 5 patients had dilated cardiomyopathy (dCMP) and 1 of them had AFI.

**Causes of Stroke in Myopathies**

**Cardioembolic Stroke**

After metabolic stroke, cardioembolic stroke is the second most frequent cause of stroke in patients with MPs. Cardioembolic stroke results from manifestations of primary or secondary MPs in the heart [3]. Cardiac involvement in MPs may affect the cardiac conduction system or, more frequently, the myocardium. Involvement of the myocardium in MPs may manifest as hypertrophic CMP, the apical form of hypertrophic CMP, left ventricular hypertrabeculation (LVHT)/non-compaction, dCMP, or restrictive CMP.

**Atrial Fibrillation/Flutter**

Involvement of the cardiac conduction system may manifest as impulse generation or impulse conduction abnormalities, which may remain subclinical and may be recorded exclusively on standard ECG, during a stress test, 24-hour ECG, or loop recording. The most relevant of these ECG abnormalities with regard to ischemic stroke is AFI/AFL [4]. AFI/AFL has been described in a number of MPs (table 1) [4], most frequently in patients with DM1, Emery-Dreifuss muscular dystrophy (EDMD), or dystrophinopathies (DMD, BMD) [4]. Primary and secondary stroke prevention in patients with MP and AFI is the same as in patients with other causes of AFI.

In a study on 18 patients with EDMD, AFI was recorded in 11 of them [5]. Four of these 11 patients (36%) developed cardioembolic stroke. One of these 4 patients had X-chromosome-linked EDMD, and 3 had autosomal-dominant EDMD [5]. All 4 patients had AFI/AFL at the time of the event [5]. Heart failure required heart transplantation in 1 of the 18 patients, and asymptomatic reduced systolic function occurred in another 3 patients [5]. The authors concluded that stroke can be the first manifestation of EDMD in young adults, and that it is frequently disabling [5]. In a patient with BMD and dCMP, ischemic stroke developed during a period of AFI [6]. Stroke in DM1, preceded by a transitory ischemic attack (TIA), was first described in a 55-year-old male and attributed to mitral valve prolapse syndrome [7]. However, AFI was also recorded in this patient, which is why a cardioembolic stroke is more likely [7]. Among 5 DMD patients experiencing stroke, 1 had AFI and dCMP [2].

**Dilated CMP**

Among all CMPs, dCMP and LVHT are the most relevant for stroke. Since hypertrophic CMP can turn into dCMP, it has to be regarded as a potential source of cardio-

<table>
<thead>
<tr>
<th>Table 1. Myopathies in which AFI/AFL has been described</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary myopathies</strong></td>
</tr>
<tr>
<td>Duchenne muscular dystrophy</td>
</tr>
<tr>
<td>Becker’s muscular dystrophy</td>
</tr>
<tr>
<td>Facioscapulohumeral dystrophy</td>
</tr>
<tr>
<td>X-linked Emery-Dreifuss muscular dystrophy</td>
</tr>
<tr>
<td>Autosomal dominant Emery-Dreifuss muscular dystrophy</td>
</tr>
<tr>
<td>Laminopathy</td>
</tr>
<tr>
<td>Limb-girdle muscular dystrophies</td>
</tr>
<tr>
<td>Myofibrillar myopathy</td>
</tr>
<tr>
<td>DM1</td>
</tr>
<tr>
<td>DM2 (PROMM)</td>
</tr>
<tr>
<td>Congenital fiber-type disproportion myopathy</td>
</tr>
<tr>
<td>Rigid spine syndrome</td>
</tr>
<tr>
<td>Desmin myopathy</td>
</tr>
<tr>
<td>Glycogenoses</td>
</tr>
<tr>
<td>Mitochondrial disorders</td>
</tr>
<tr>
<td>Barth syndrome</td>
</tr>
<tr>
<td><strong>Secondary myopathies</strong></td>
</tr>
<tr>
<td>Dermatomyositis</td>
</tr>
<tr>
<td>Polymyositis/dermatomyositis</td>
</tr>
<tr>
<td>Polymyositis</td>
</tr>
<tr>
<td>Colchicine-induced rhabdomyolysis</td>
</tr>
<tr>
<td>Hyperthyroid myopathy</td>
</tr>
</tbody>
</table>

Stroke in Myopathies
embolism in patients with MPs as well. CMPs may be relevant for the development of stroke because they are frequently associated with reduced systolic function and AFI/AFL. Reduced systolic function may cause cardioembolic stroke in cases of intracardiac thrombus formation or because of hemodynamic reasons. MPs in which dCMP has been described so far are listed in Table 2. dCMP most frequently occurs in dystrophinopathies, mitochondrial disorders (MIDs), and limb-girdle muscular dystrophies [3].

Stroke in association with dCMP has been also described in a patient with Barth syndrome, who was in sinus rhythm at the time of the event [8]. Stroke in association with dCMP was also described in 2 patients with DMD (DMD sufferers develop dCMP by about 20 years of age in almost 100% of cases [9]). In 1 of these patients, stroke occurred at 21 years of age at an ejection fraction (EF) <20%, during sinus rhythm, and together with increased thrombin-ATIII complexes and increased D-dimer [10]. The second DMD patient experienced a TIA at 21 years of age, and 5 months later completed ischemic stroke. His EF was also <20%, he was in sinus rhythm, and also had increased thrombin-ATIII complexes and D-dimer [10]. Ischemic stroke in the absence of AFI/AFL was also reported in a 13-year old DMD patient, in whom the EF was 35–40% at the time of the event [11]. Five months later, the patient experienced a minor stroke in the same vascular territory as before [11]. dCMP was the cardiac abnormality made responsible for stroke in 5 DMD patients, aged 16–20 years, of whom 1 additionally had AFI/AFL. Generally, dCMP seems to create a predisposition towards ischemic stroke, irrespective of its cause. In a study of 72 patients with dCMP, the prevalence of silent cerebral infarction was 39 and 27% in patients with ischemic and non-ischemic dCMP, respectively, and significantly increased compared to controls (3.6%) [12]. Systolic function was lower in patients with silent cerebral infarction than without, and a restrictive diastolic filling pattern predisposed patients to silent cerebral infarction [12].

Left Ventricular Hypertrabeculation/Non-Compaction

LVHT, also known as non-compaction, describes a cardiac abnormality of the left ventricular apex, the lateral wall, and (rarely) the septum that is characterized by a meshwork of interwoven myocardial strings lined with endocardium, which constitutes a spongy myocardial layer at the endocardial side, clearly distinct from the underlying compacted myocardium at the epicardial side (2-layered myocardium) [3, 13–15]. In up to 82% of the LVHT patients, an MP can be detected. MPs so far associated with LVHT are MIDs, dystrophinopathies, DM1, DM2, EDMD, zaspopathy, dystrobrevinopathy, Barth syndrome, or myoadenylate-deaminase deficiency [16]. LVHT is frequently associated with ECG abnormalities (75% of newborns with LVHT) [3, 15, 17, 18], systolic dysfunction (83% of the children with congenital LVHT), or occasionally also with stroke/embolism [3, 15, 18]. Stroke in LVHT may not only derive from AFI/AFL or systolic dysfunction, but also from thrombus formation within the recessus of the myocardial meshwork.

Whether or not the risk of stroke is increased in patients with LVHT is controversial. Some studies found no increased frequency of stroke in LVHT patients [19–21], whereas others, particularly case reports, indicated an increased risk of developing a stroke (Table 3) [22–25]. In a retrospective study of 229 patients with LVHT, of which those with AFI/AFL were excluded, only 4 patients had developed ischemic stroke during a mean follow-up of 7.3 years [19]. In a retrospective study on 62 LVHT patients, the incidence of stroke was 10% in patients and 15% in controls matched for age, sex and systolic function [21]. Whether or not patients with LVHT should generally receive oral anticoagulation (OAC) is controversial. Though OAC have been frequently proposed for patients with LVHT [26], these recommendations rely only on single case reports or small case series. According to our own experience, there is no general indication for OAC in LVHT patients as long as classical indications for OAC therapy are absent [14, 20].

Angiopathic Stroke

Angiopathies associated with stroke in MP patients include atherosclerosis, which frequently occurs in MIDs.
and DM1 in the presence of classical cardiovascular risk factors, dissection, or vasculitis in inflammatory MPs, such as polymyositis or dermatomyositis.

**Polymyositis**

A 53-year-old patient with polymyositis experienced cerebral hemorrhage and dissection of the right external iliac and right renal arteries. These findings were attributed to necrotizing angiitis [27]. Coarctation of the aorta, aortic stenosis, bicuspid aortic valve, and Marfan syndrome were excluded as possible causes of the arteriopathy. There was only mild arteriosclerosis and no cystic necrosis of the aortic media or other arteries. The only risk factor other than polymyositis for the development of necrotic angiitis was long-term therapy with steroids [27]. In a patient with polymyositis, 18 years after the onset of rheumatoid arthritis, the history was positive for stroke and myocardial infarction after high-dose steroids. Whether stroke was due to vasculitis or due to steroid-induced diabetic angiopathy in these patients remains elusive [28].

**Dermatomyositis**

In cases of intractable dermatomyositis, cerebral vasculitis may develop. A 47-year-old female with dermatomyositis developed ischemic stroke, attributed to cerebral vasculitis and confirmed by conventional angiography and biopsy of the cerebrum [29]. Dermatomyositis and vasculitis responded favorably to cyclophosphamide [29]. Acute ischemic stroke was also reported in another 47-year-old female with dermatomyositis, who received intravenous immunoglobulins when the stroke developed, which was why it remained unclear if the stroke was due to this treatment or concomitant vasculitis [30].

**Mitochondrial Angiopathy**

Whether there is a distinct mitochondrial macro- or micro-angiopathy is under debate at the moment. However, classical cardiovascular risk factors – such as diabetes, arterial hypertension, and hyperlipidemia – are frequently present in a number of syndromic and non-syndromic MIDs [31]. There are also patients with MID who developed severe atherosclerosis in the absence of classical cardiovascular risk factors [32]. In these cases, atherosclerosis could be a manifestation of the underlying MID, an assumption for which some evidence has been provided [33]. There are also some indications for mitochondrial microangiopathy, but the majority of the studies argue against such an entity in the pathogenesis of stroke-like episodes (SLEs). In a patient with MELAS syndrome due to a mtDNA tRNA(Phe) mutation and an absence of classical atherothrombotic risk factors, recurrent embolic ischemic strokes developed because of carotid artery stenosis and artery-to-artery embolism into the middle and anterior cerebral artery [34].

**Thrombophilic Stroke**

When studying the coexistence of polymyositis/dermatomyositis and antiphospholipid syndrome in a cohort of patients, 3 patients presented with both conditions. One of these 3 patients not only developed livedo reticularis, recurrent abortions, and mitral regurgitation, but also isch-
emic stroke. The patient additionally had lupus erythematosus [35]. Whether MP patients immobilized due to general weakness more frequently develop stroke than mobile patients with MPs is currently unresolved. Recent studies concerning this matter have shown that prophylactic anticoagulation is necessary only during the first 4 months following onset of the immobility in all immobile neurological patients, regardless of their muscle tone [36]. The dramatic drop in the risk of venous thromboembolism 3–4 months after onset of the immobility is attributed to vascular changes following long-term inactivity [36].

**Cryptogenic Stroke**

A 4-year-old DMD patient developed pontine stroke 3 times within 1 year [37]. Left ventricular function was normal and there was no indication of AFI/AFL [37]. In this case, the diagnosis of DMD is questionable since immunohistochemistry and genetic testing for dystrophin were not available at the time of diagnosis. A 41-year-old male with DM1 experienced a TIA manifesting as aphasia and right-sided hemi-syndrome for 2 h [38]. Though the authors attributed the cerebrovascular event to mitral valve prolapse syndrome, the proposed causal relation remains questionable.

**Metabolic Stroke**

Metabolic stroke is a typical phenotypic feature of MIDs, where it manifests as SLE [39]. SLEs are usually non-ischemic events, characterized by increased capillary permeability, hyperperfusion, neuronal hyperexcitability, and neuronal loss [40]. SLEs present not only with classical clinical features of ischemic stroke, but frequently with additional features, such as epileptic seizures, ataxia, migraine-like headache, visual impairment, amnesia, cognitive impairment, psychosis, hallucinations, confusional state, or coma. SLEs are episodic events and occur most frequently in MELAS syndrome and mimics ischemic stroke, but are largely different concerning imaging, treatment, and prognosis [41]. Other MIDs in which SLEs have been reported include MERRF syndrome, Kearns-Sayre syndrome, and Leigh syndrome [42].

Though the pathogenesis of SLEs is under debate [43], there is consensus that the cerebral lesions seen on imaging (stroke-like lesions, SLLs) represent vasogenic edema. Vasogenic edema may result from mitochondrial microangiopathy, which may lead to cerebral hyperperfusion and thus hypoxia and capillary leakage [44]. Arguments against mitochondrial angiopathy are that ischemic lesions within SLLs are rare, that the prevalence of ischemic stroke is not increased in MIDs, that most MID patients with an SLE have no mitochondrial angiopathy on autopsy, and that cerebral blood flow during or after an SLE is either normal or increased on appropriate perfusion studies [39, 45, 46]. Arguments in favor of mitochondrial angiopathy are that SLLs may occasionally contain ischemic lesions and that COX deficiency and heteroplasmy rates are highest in leptomeningeal or cortical arteries [47]. Most likely, however, an SLE is not due to mitochondrial angiopathy with functional disturbance of arterioles resulting in an ischemic event [48]. According to a second hypothesis, SLE are due to a local metabolic defect in energy production resulting in anaerobic metabolism, neuronal damage or death from acidosis [39], and consecutively hyperperfusion and vasogenic edema [49]. According to a third hypothesis, SLLs result from focal neuronal hyperexcitability, demanding increased provision of energy, and resulting in a mismatch between demand and availability of energy [43, 50]. An argument in favor of the ‘epilepsy’ hypothesis is that focal epileptiform discharges are recorded in up to 80% of patients during an SLE [50].

In the acute stage of an SLL, MRI shows hyperintensity on T2, DWI, and apparent diffusion coefficient (ADC) mapping, indicating a vasogenic edema [49]. The ADC may remain high even months after onset [49] to become hypointense or alternatively hyperintense in the chronic stage. Occasionally, SLL may go along with petechial or intracortical gyral hemorrhage [43]. In single cases, there may be coexistence of cytotoxic and vasogenic edema within the same SLL [51], particularly at onset of an SLE [52]. The ADC is helpful to differentiate between ischemic stroke (hypointense ADC) and extracellular edema (hyperintense ADC) [53]. SLLs are most frequently located in the parieto-occipital region and show a characteristic dynamic spread to other homo- or contralateral regions [39]. At the end of an SLE, MRI may completely normalize or evolve into laminar cortical necrosis [43], T2 white matter hyperintensities, or cysts.

Perfusion studies by perfusion MRI, HMPAO-SPECT, xenon CT, or PET may be either normal or show focal cortical hyperperfusion in the acute stage of an SLL [43, 45, 46, 49]. In the chronic stage of an SLL, diffuse hypoperfusion may be the characteristic feature [54]. Conventional angiography or MRA are usually normal in patients with SLEs [55].

H-MRS of an SLL may show a reduced N-acetyl-aspartate (NAA)/creatin (Cr) ratio and an increased lactate peak [49, 56]. In the later stages of an SLL, the NAA/ Cr ratio may gradually increase together with a decrease in the ADC [49]. In several patients, the increase in lactate and glucose and the decrease of NAA, glutamate, or
Cr are not restricted to the SLL, but may occur ubiquitously within the brain [57].

Due to the lack of prospective controlled studies, there is no agreement on the treatment of SLEs. So far, SLLs have been managed by application of remedy cocktails made up of coenzyme Q, idebenone, L-arginine, tocopherol nicotinate, edaravone, prednisolone, glycerol, ATP, cytochrome C, flavin mononucleotide, thiamine dipospho- 
ite, biotin, carnitine, or dichloracetate in various combinations. In other studies, some of these agents have been given in monotherapy, such as creatine monohydrate, cysteamine, or succinate [58]. A recent Cochrane review of 678 abstracts has shown that there is no objective evidence to support the use of coenzyme Q, creatine monohydrate, dichloroacetate, or dimethylglycine for the treatment of MIDs [59].

Conclusions

Ischemic stroke may be only a rare phenotypic feature of MPs and most frequently occurs in DM1, dystrophinopathies, and MIDs. Metabolic stroke, however, is a dominant feature of various syndromic MIDs, and should be increasingly recognized since the prevalence of MIDs will increase due to improved diagnostic facilities and increasing awareness of MIDs in general. Since SLEs, which may result in a state of disability, characteristically spread and recur, and as there is no effective therapy currently available, all efforts should be directed towards research into the development of targeted, safe and immediately effective agents or a therapeutic concept enabling clinicians to provide support and not to administer unproven medication with unknown side effects.

Appendix: Primary Myopathies

(1) Muscular Dystrophies (MD)/Dystrophinopathies
Duchenne MD, Becker’s MD, X-linked Emery-Dreifuss MD, autosomal-dominant Emery-Dreifuss MD, facioscapulohumeral MD, autosomal-dominant limb-girdle MD, autosomal-recessive limb-girdle MD, and congenital muscular dystrophies (CMDs: CMD with merosin deficiency, CMD with abnormal glycosilation of dystroglycan, Fukuyama CMD, Walker Warburg syndrome, muscle eye-brain disease, rigid spine syndrome, Ullrich syndrome, Bethlem MP, and CMD with integrin deficiency).

(2) Congenital Myopathies
Nemaline MP, congenital MP with fiber-type disproportion, myotubular MP, centronuclear MP, central core disease (CCD), multiminicore disease, and hyaline body MP.

(3) Distal Myopathies
Distal recessive MP (Myoshi), tibial muscular dystrophy (Udd), distal MP with rimmed vacuoles (Nonaka), hereditary inclusion body MP, distal MP (Laing), vocal cord and pharyngeal distal MP, adult-onset distal MP, Welander distal MP, distal MP with pes cavus and areflexia (vaccuolar neuromyopathy), and distal MP with myotilin defect.

(4) Myofibrillar Myopathies
α-Cristalline-related myofibrillar MP, desmin-related myofi- 
brillar MP, desmin-related MP with Mallory bodies, myofibrillar MP with arrhythmogenic right ventricular cardiomyopathy, myotilin-related myofibrillar MP, spheroid body MP, and filamin-C-related myofibrillar MP.

(5) Autophagic Vacuolar Myopathies
Danon’s disease and MP with excessive autophagia.

(6) Myotonic Syndromes
DM1, DM2, Thomson, Becker (see ‘7’), rippling muscle disease, Schwartz-Jampel syndrome, and Brody disease.

(7) Ion Channel Muscle Diseases
Cl channel (Thomson, Becker), Na channel (hyperPP, Eulen- 
burg, K-aggravated myotonia, LQT-syndromes), Ca channel (hypopPP), K channel (hypopPP3, episodic ataxia/myokymia, Anderson’s syndrome, and long QT syndromes).

(8) Malignant Hyperthermia

(9) Metabolic Myopathies
• Glycogenoses [II (Pompe), IIIa, IV, V (McArdle disease), VII (Tarui), phosphoglycerate kinase deficiency, phosphoglycerate mutase deficiency].
• Glycolytic pathway (lactate dehydrogenase deficiency, enolase deficiency).
• Lipid metabolism [carnitine-palmitoyltransferase (CPT)-deficiency, primary systemic carnitine deficiency, carnitine-acyl- 
carnitine-translocase (CACT)-deficiency, multiple acyl-CoA dehydrogenase deficiency (MADD), very long chain acyl-CoA dehydrogenase deficiency (VLCAD), Chanarin-Dorfman syndrome).

(10) Mitochondrial MP

(11) Unclassified
Oculopharyngeal muscular dystrophy, MP with proximal atro- 
phy and early respiratory muscle involvement (Edström), epi- 
dermiolysis bullosa simplex, muscle hypertrophy, fibrodyplasia ossificans progressiva, idiopathic hyperCKemia, McLeod syn- 
drome, and Barth syndrome.
References


32 Gaber TA: Significant reduction of the risk of venous thromboembolism in all long-term immobile patients a few months after the onset of immobility. Med Hypotheses 2005; 64:1173–1177.


